Head and Neck Cancer Therapeutics Market to Surpass USD 2934.26 Million by 2026
Increasing cases of head and neck cancer and spike in demand for combination therapy is expected to drive Global Head and Neck Cancer Therapeutics Market.
According to TechSci Research report, “Global Head and Neck Cancer Therapeutics Market By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others), By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer), By Route of Administration (Injectable, Oral), By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centres, Others), By Region, Forecast & Opportunities, 2026”, the market is anticipated to witness a robust CAGR of 7.71% during the forecast period. The growth in global head and neck cancer therapeutics market can be attributed to rising prevalence of head and neck cancer around the world and growing geriatric population, which is more vulnerable to cancer. At present, more than 43 products are undergoing clinical trials for the head and neck cancer therapeutics market. In some cases, early diagnosed cancers are curable but the treatment varies on the basis of extent, location and type of the disease. Latest advances in surgical techniques and nonsurgical therapies such as targeted therapy and immunotherapy aid in preserving the quality of life while offering the most effective care. Apart from this, technological advancements in the screening procedure for cancer and various pipeline drugs such as Atezolizumab, Erlotinib, Ipilimumab, Durvalumab, Avelumab, Afatinib, Bevacizumab, and others will have a positive impact on the market which will further drive the market growth.
Moreover, governments and private organizations’ initiative to provide improved healthcare service and beneficial healthcare reforms are supporting the growth of the global head and neck cancer therapeutics market. Also, growing popularity of immunotherapy for head and neck cancer treatment is expected to provide huge growth opportunities for pharmaceutical companies. Furthermore, cancer awareness programs and early cancer diagnosis are acting as some other key growth drivers for head and neck cancer therapeutics market.
Browse and 190 Figures spread through 110 Pages and an in-depth TOC on “Global Head and Neck Cancer Therapeutics Market”
https://www.techsciresearch.com/report/head-and-neck-cancer-therapeutics-market/5056.html
The global head and neck cancer therapeutics market is segmented based on diagnostic methods, treatment type, disease indication, route of administration, therapeutic class, end user and region. Based on disease indication, the market can be segmented into laryngeal cancer, lip and oral cavity cancer, nasopharyngeal cancer, oropharyngeal cancer, salivary gland cancer and others. Among them, lip and oral cavity cancer is expected to contribute largest share through 2026 due to a large patient pool affected by lip and oral cancer globally.
Based on therapeutic class, global head and neck cancer therapeutics market can be segmented into PD inhibitors, microtubule inhibitors and EGFR inhibitors. Among them, PD inhibitor drug class is expected to grow significantly during the forecast period owing to new product launches.
Major players operating in the global head and neck cancer therapeutics market include AstraZeneca Plc., Astellas Pharma Inc., AB Science SA, Bristol-Myers Squibb Company, Boston Biomedical, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Fresenius Medical Care AG & Co. KGaA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Bayer AG and AbbVie Inc. The players are undergoing extensive R&D activities to develop new therapeutic drugs and increase their global market share.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5056
Customers can also request for 10% free customization on this report.
“North America is expected to contribute to the largest share in the global head and neck cancer therapeutics market as United States is witnessing high prevalence HPV-induced cancers. However, Asia Pacific is expected to register fastest CAGR during the forecast period owing to rising incidences of head & neck cancer. The risk factors such as increase in cigarette smoking and usage of tobacco is also making the region a lucrative market for drug manufacturing companies,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Global Head and Neck Cancer Therapeutics Market By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others), By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer), By Route of Administration (Injectable, Oral), By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centres, Others), By Region, Forecast & Opportunities, 2026”has evaluated the future growth potential of global head and neck cancer therapeutics market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in the global head and neck cancer therapeutics market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com/
